Persistence of Hepatitis C RNA in Liver Allografts Is Associated with Histologic Progression Independent of Serologic Viral Clearance

Table 2

Antiviral therapy timing, duration, dose reductions, growth factor use, and virologic outcomes in treated group 1 and 2 patients.

Variable	Group 1 ISH positive 𝑁=10	Group 2 ISH negative 𝑁=15	𝑃
Pegylated IFN	100%	86%	.23
Dose reduction	40%	33%	.73
Growth factors used	80%	73%	.70
LT-Treatment interval, months	6 ± 3	9 ± 7	.35
Treatment duration at ISH biopsy months	13 ± 6	10 ± 4	.24
Total treatment duration	24 ± 10	14 ± 5	.001
EVR	90%	86%	.75
ETR	90%*	100%	NA
SVR	80%*	60%	.29

^∗1 patient was still on treatment at last follow up.